Flecainide

Flecainide
Clinical data
Pronunciation	/flɛˈkeɪnaɪd/ fleh-KAY-nyde
Trade names	Tambocor, others
AHFS/Drugs.com	Monograph
MedlinePlus	a608040
Drug class	Ic antiarrhythmic
ATC code	C01BC04 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: WARNINGRx-only;
Pharmacokinetic data
Bioavailability	95%
Protein binding	40%
Metabolism	CYP2D6 (limited)
Elimination half-life	20 hours (range 12–27 hours)
Excretion	Kidney
Identifiers
	IUPAC name (RS)-N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide;
CAS Number	54143-55-4 ;
PubChem CID	3356;
IUPHAR/BPS	2560;
DrugBank	DB01195 ;
ChemSpider	3239 ;
UNII	K94FTS1806;
KEGG	D07962 ;
ChEBI	CHEBI:75984 ;
ChEMBL	ChEMBL652 ;
CompTox Dashboard (EPA)	DTXSID8023054 ;
ECHA InfoCard	100.211.334
Chemical and physical data
Formula	C17H20F6N2O3
Molar mass	414.348 g·mol−1
3D model (JSmol)	Interactive image;
Chirality	Racemic mixture
	SMILES FC(F)(F)COc2cc(C(=O)NCC1NCCCC1)c(OCC(F)(F)F)cc2;
	InChI InChI=1S/C17H20F6N2O3/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26) ; Key:DJBNUMBKLMJRSA-UHFFFAOYSA-N ;
	(what is this?) (verify)

Flecainide is a medication used to prevent and treat abnormally fast heart rates. This includes ventricular and supraventricular tachycardias. Its use is only recommended in those with dangerous arrhythmias or when significant symptoms cannot be managed with other treatments. Its use does not decrease a person's risk of death. It is taken by mouth or injection into a vein.

Common side effects include dizziness, problems seeing, shortness of breath, chest pain, and tiredness. Serious side effects may include cardiac arrest, arrhythmias, and heart failure. It may be used in pregnancy, but has not been well studied in this population. Use is not recommended in those with structural heart disease or ischemic heart disease. Flecainide is a class Ic antiarrhythmic agent. It works by decreasing the entry of sodium in heart cells, causing prolongation of the cardiac action potential.

Flecainide was approved for medical use in the United States in 1985. It is available as a generic medication. In 2021, it was the 205th most commonly prescribed medication in the United States, with more than 2 million prescriptions.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.